Arvinas, Inc. (ARVN)
NASDAQ: ARVN · Real-Time Price · USD
17.77
-0.60 (-3.27%)
At close: Feb 21, 2025, 4:00 PM
17.53
-0.24 (-1.35%)
After-hours: Feb 21, 2025, 6:38 PM EST
Arvinas Revenue
In the year 2024, Arvinas had annual revenue of $263.40M with 235.54% growth. Arvinas had revenue of $59.20M in the quarter ending December 31, 2024, a decrease of -237.35%.
Revenue (ttm)
$263.40M
Revenue Growth
+235.54%
P/S Ratio
4.85
Revenue / Employee
$612,558
Employees
430
Market Cap
1.22B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 263.40M | 184.90M | 235.54% |
| Dec 31, 2023 | 78.50M | -52.90M | -40.26% |
| Dec 31, 2022 | 131.40M | 77.80M | 145.15% |
| Dec 31, 2021 | 53.60M | 27.70M | 106.95% |
| Dec 31, 2020 | 25.90M | -17.10M | -39.77% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
ARVN News
- 9 days ago - These Analysts Revise Their Forecasts On Arvinas After Q4 Results - Benzinga
- 10 days ago - Arvinas, Inc. (ARVN) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 11 days ago - Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 19 days ago - Arvinas to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025 - GlobeNewsWire
- 6 weeks ago - Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium - GlobeNewsWire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Arvinas, Inc. (ARVN) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 2 months ago - Arvinas, Inc. (ARVN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire